2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
The 2026 ADA/EASD consensus report on type 2 diabetes management now recommends screening adults for hypercortisolism when diabetes remains difficult to control despite multiple glucose-lowering medications. The report cites Corcept's CATALYST trial: in 136 randomized patients, mifepristone (Korlym) reduced HbA1c by 1.47 percentage points vs 0.15 on placebo (difference -1.32, p<0.001), and screening identified hypercortisolism in 24% of difficult-to-control patients.
Key figures
- Drug Name
- Korlym (mifepristone)
- Phase Of Trial
- Phase 3 (CATALYST)
- Catalyst screened patients
- 1057
- Hba1c reduction mifepristone
- -1.32 percentage points vs placebo (p<0.001)
- Hypercortisolism prevalence difficult t2d
- 24%
- Hypercortisolism prevalence t2d plus hypertension
- 37%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.